Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial

Bone Marrow Transplantation

Volumn 25, Issue 8, 2000, Pages 879-884

  Timmers, G J ^a   Zweegman, S ^a   Simoons Smit, A M ^a   Van Loenen, A C ^a   Touw, D ^a   Huijgens, P C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABCD; Amphocil; Neutropenia; Prophylaxis; Toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; ANTIHISTAMINIC AGENT; FLUCONAZOLE; HYDROCORTISONE; MORPHINE;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; MALE; MORTALITY; MYCOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; VOMITING;

EID: 0034035331     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702243     Document Type: Article

References (29)

1. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin N Am 1996; 10: 365-400.
2. DeGregorio MW, Lee WM, Linker CA et al. Fungal infections in patients with acute leukemia. Am J Med 1982; 73: 543-548.
3. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
4. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
5. Huijgens PC, van Loenen AC, Simoons-Smit AM et al. The prophylactic use of fluconazole 50 vs 100 mg daily in haematological malignancies. Eur J Cancer 1993; 29A: 926-927.
6. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplanation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 14: 919-924.
7. Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994; 120: 913-918.
8. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-1041.
9. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545-1552.
10. Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52: 376-380.
11. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503.
12. Perfect JR, Klotman ME, Gilbert CC et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891-897.
13. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-192.
14. Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-514.
15. Bowden RA, Cays M, Gooley T et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996; 173: 1208-1215.
16. Herbrecht R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997; 16: 74-80.
17. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-1153.
18. Anaissie EJ, Mattiuzzi GN, Miller CB et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998; 42: 606-611.
19. Noskin G, Pietrelli L, Gurwith M, Bowden R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999; 23: 697-703.
20. Tollemar J, Ringden O, Andersson S et al. Randomised double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
21. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
22. Arning M, Heer-Sonderhoff AH, Wehmeier A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 41-43.
23. Ringden O, Andstrom E, Remberger M et al. Allergic reactions and other rare side-effects of liposomal amphotericin. Lancet 1994; 344: 1156 (letter).
24. White MH, Bowden RA, Sandler ES et al. Randomised, double blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
25. Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leukemia Res 1997; 21: 183-188.
26. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570-1575.
27. Ringden O, Jonsson V, Hansen M et al. Severe and common side-effects of Amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998; 22: 733 (letter).
28. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459-465.
29. Chia JK, McManus EJ. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990; 34: 906-908.